Immunogenic compositions and uses thereof

a technology of compositions and compositions, applied in the field of0003nucleic acid based vaccines, can solve the problems of uncontrollable undesirable sustained expression of antigens, and inability to rule out the risk of uncontrolled propagation of introduced genes and viral genes, so as to enhance the immune response to the pathogen

Pending Publication Date: 2021-09-23
GLAXOSMITHKLINE BIOLOGICALS SA
View PDF0 Cites 40 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The patent is about a new way to make vaccines that can better protect against disease. The vaccine contains two different forms of the disease-causing agent, one in RNA code and one in protein form. When both forms are used, the vaccine makes a stronger immune response than either RNA or protein alone. The two forms are ideally the same and should give the best protection against the disease.

Problems solved by technology

DNA vaccines are generally effective in generating cell mediated immunity (such as interferon-γ secreting antigen-specific T-cells and antigen-specific cytotoxic T-cells), but less effective in generating antibodies against the encoded and expressed antigen.
The introduced DNA molecules could potentially integrate into the host genome or, due to their distribution to various tissues, could lead to undesirable sustained expression of antigens.
Despite these precautions, however, it is not possible to rule out the risk of uncontrolled propagation of the introduced gene and viral genes, for example due to potential recombination events.
This also entails the risk of the DNA being inserted into an intact gene of the host cell's genome by e.g. recombination, with the consequence that the host gene may be mutated and thus completely or partially inactivated or may give rise to misinformation.
However, compared with DNA-based vaccines, relatively minor attention has been given to RNA-based vaccines.
RNAs are highly susceptible to degradation by nucleases when administered as a therapeutic or vaccine.
Additionally, RNAs are not actively transported into cells.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Immunogenic compositions and uses thereof
  • Immunogenic compositions and uses thereof
  • Immunogenic compositions and uses thereof

Examples

Experimental program
Comparison scheme
Effect test

example i

stration of RNA and Protein to Mice

[0418]In this example, an RNA molecule encoding the RSV-F, or an RNA molecule encoding the GFP protein, was co-administered with an RSV-F antigen in polypeptide form. The effects of RNA on its “cognate” antigen and “non-cognate” antigen were assessed. The RSV-F antigen is a “non-cognate” antigen of the GFP-coding RNA because the F antigen does not share sequence homology to, and does not immunologically cross-react with the polypeptide encoded by the RNA molecule (GFP).

[0419]Three RNAs were used for this study: the vA317 replicon that expresses the surface fusion glycoprotein of RSV (RSV-F); the vA17 replicon that expresses green fluorescent protein (GFP); and the vA336 replicon that is replication-defective and encodes GFP. BALB / c mice, 5 animals per group, were given bilateral intramuscular vaccinations (50 μL per leg) on days 0 and 21. Spleens were harvested at day 49 for T cell analysis. Animals, 70 total, were divided into 14 groups (5 animals...

example ii

tration of RNA and Protein and Sequential Administration of RNA and Protein to Mice

[0438]The vA142 replicon was used for this study. This construct expresses the full-length wild type surface fusion glycoprotein of RSV with the fusion peptide deleted and the 3′ end of the replicon is formed by ribozyme-mediated cleavage. BALB / c mice, 116 total, were divided into 11 groups (4-22 animals per group).

[0439]Group 1 (8 animals) were given bilateral intramuscular vaccinations (50 μL per leg) on days 0, 21 with unadjuvanted RSV-F subunit protein vaccine (3 μg) and all animals were sacrificed at day 42.

[0440]Group 2 (22 animals) were given bilateral intramuscular vaccinations (50 μL per leg) on days 0, 21 with the RSV-F subunit protein vaccine (3 μg) adjuvanted with alum. 4 animals were sacrificed at day 42. 6 mice were given a third vaccination at day 42 with the RSV-F subunit protein vaccine (3 μg) adjuvanted with alum and the animals were sacrificed at day 63. 6 mice were given a third va...

example iii

Administration of RNA and Protein to Rats (Study 1)

[0463]Three different replicons were used for this study: the vA317 replicon, which expresses the full-length wild type surface fusion glycoprotein of RSV (RSV-F); the vA318 replicon, which expresses the truncated (transmembrane and cytoplasmic tail removed) surface fusion glycoprotein of RSV; and the vA142 replicon, which expresses the full-length wild type surface fusion glycoprotein of RSV with the fusion peptide deleted. Cotton rats, 2-8 animals per group, were given intramuscular vaccinations (100 μL in one leg) on days 0 and 21 with the three different RNAs (vA317, vA318, vA142) formulated in LNPs (RV01(29) or CNE17 (N:P ratio 10:1) and given at two doses (1.0 and 0.1 μg, 8 animals / group). LNPs had the following composition: 40% DlinDMA, 10% DSPC, 48% Chol, 2% PEG DMG 2000, N:P ratio of 8:1 and was made using Method B, except a 150 μg RNA batch size was used. Control groups received the RSV-F subunit protein vaccine (5 μg) adj...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

This invention generally relates to immunogenic compositions that comprise an RNA component and a polypeptide component. Immunogenic compositions that deliver antigenic epitopes in two different forms—a first epitope from a pathogen, in RNA-coded form; and a second epitope from the same pathogen, in polypeptide form—are effective in inducing immune response to the pathogen. The invention also relates to a kit comprising an RNA-based priming composition and a polypeptide-based boosting composition. The kit may be used for sequential administration of the priming and the boosting compositions.

Description

RELATED APPLICATION[0001]This application is a continuation of U.S. application Ser. No. 14 / 130,869 filed Apr. 15, 2014, which is the U.S. National Phase of International Application No. PCT / US2012 / 045854 field Jul. 6, 2012, which claims the benefit of U.S. Provisional Application No. 61 / 505,105 filed on Jul. 6, 2011; the entire contents of the foregoing applications are incorporated herein by reference.SEQUENCE LISTING[0002]The instant application contains a Sequence Listing which has been submitted in ASCII format via EFS-Web and is hereby incorporated by reference in its entirety. Said ASCII copy, created on Jul. 5, 2012, is named PAT54514.txt and is 92,631 bytes in size.BACKGROUND OF THE INVENTION[0003]Nucleic acid based vaccines are an attractive approach to vaccination. For example, intramuscular (IM) immunization of plasmid DNA encoding an antigen can induce cellular and humoral immune responses and protect against challenge. DNA vaccines offer certain advantages over traditi...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K39/155A61K39/245A61K39/12A61P31/20A61P31/14
CPCA61K39/155A61K39/245A61K2039/53A61P31/20A61P31/14A61K39/12A61K2039/545A61K2039/55505A61K2039/55555A61K2039/55566A61K2039/55588C12N2710/16134C12N2760/18534C12N2770/36143
Inventor GEALL, ANDREWOTTEN, GILLISBARNETT, SUSAN
Owner GLAXOSMITHKLINE BIOLOGICALS SA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap